Background--Several metabolic conditions can cause the Brugada ECG pattern, also called Brugada phenotype (BrPh). We aimed to define the clinical characteristics and outcome of BrPh patients and elucidate the mechanisms underlying BrPh attributed to hyperkalemia.
However, other studies found no clear genetic association, and minor structural abnormalities were associated with the syndrome. [6] [7] [8] Moreover, some environmental factors can induce ECG morphologies similar or identical to BrS in the absence of genetic mutations or ion-channel dysfunction. 6, 9 The acquired form of Brugada-like ECG pattern, also called Brugada phenotype (BrPh), is manifested by a Brugada ECG pattern in the presence of an identifiable underlying condition and typically disappears after its resolution. 3, 4, [10] [11] [12] Multiple metabolic conditions can lead to BrPh ECG; the majority of cases are associated with serum K + abnormalities, hyperkalemia being the most frequent single cause. 10 Although classical hyperkalemia produces several well-described ECG alterations, only a minority of patients develop BrPh. 10, 12 Nevertheless, the clinical characteristics and prognostic impact on patients developing BrPh are poorly known. The main mechanism responsible for BrS phenotype relate to abnormal patterns of repolarization and/or impulse activation at the right ventricular outflow tract (RVOT). [13] [14] [15] [16] However, whether BrPh represents transient alterations in myocardial depolarization, repolarization, or any other mechanism is yet to be elucidated. Moreover, the transient nature of BrPh casts doubt about its genetic origin or relation to structural abnormalities, or both.
The objectives of the study were several fold, including to: (1) describe the clinical and ECG characteristics and clinical outcome of patients with hyperkalemic BrPh; (2) compare the clinical characteristics of patients with hyperkalemic BrPh with those of patients with severe hyperkalemia but no BrPh ECG; (3) conduct computer simulations in a three-dimensional model of ventricular propagation under conditions of varying hyperkalemia to analyze the implication of mutations and/or structural abnormalities in relation to the Brugada sign 17 ;
(4) study the mechanisms underlying hyperkalemic BrPh; and (5) evaluate the proarrhythmic risk of BrPh in the presence of hyperkalemia.
Methods
Data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data will be made available for requests made to corresponding author by e-mail.
Patients
From 2010 to 2016, we prospectively identified patients hospitalized at our institution who presented an ECG suggestive of BrS in the context of severe hyperkalemia (group 1). Inclusion in this series required moderate-to-severe hyperkalemia (serum potassium [K + ] ≥6.5 mmol/L), hospitalization for an acute illness and type 1 or 2 Brugada ECG pattern on right precordial leads V1 to V2, which normalized after serum K + levels returned to reference values. 10 Additionally, we also considered patients with atypical ST-segment elevation on the right precordial leads without BrS and/or aVR sign. 18, 19 Furthermore, we retrospectively reviewed the charts of all adults admitted to our center during 2013 who developed severe hyperkalemia any time during admission, with an available ECG recording at peak serum K + ≥6.5 mmol/L (group 2).
For all patients, we recorded demographic and clinical characteristics, laboratory data, treatments, and hospital outcomes, including diagnosis at discharge and survival status. The ECGs obtained during peak serum K + were analyzed for rate, rhythm, P-wave voltage, PR interval duration, QRS width, QRS axis, QTc interval, maximum height of ST-segment elevation, and T wave height. In group 1 patients, the recorded ECGs were compared before and after treatment of hyperkalemia. In group 1 patients displaying a BrPh ECG, a provocative flecainide test was performed after normalization of the electrolyte disturbances. Patients were considered to be at a low clinical probability of having BrS if they had a negative flecainide challenge test, a lack of family history of syncope or sudden death, no previous history of syncope or cardiac arrhythmia, and normal body temperature. 10 The institutional review board of our center waived the informed consent form and approved the study.
Clinical Perspective
What Is New?
• In patients with severe hyperkalemia resulting from a critical medical condition, the presence of a Brugada syndrome ECG phenotype is associated with a high prevalence of malignant arrhythmias and all-cause mortality.
• Higher serum potassium levels and male sex are independent predictors for the presence of a Brugada ECG phenotype.
• Modeling studies indicate that the Brugada ECG phenotype induced by severe hyperkalemia occurs secondary to membrane depolarization and consequent reduced sodium channel availability, resulting in delayed and heterogeneous conduction, particularly in the presence of fibrosis at the right ventricular outflow tract.
What Are the Clinical Implications?
• Prompt recognition of this clinical-morphological entity and immediate treatment of hyperkalemia and surveillance of potential life-threatening arrhythmias is strongly recommended.
• Drug-provocation testing following normalization of serum potassium levels may be considered to uncover underlying Brugada syndrome.
Computer Simulations
A multiscale computer model was constructed to determine conditions for the BrPh ECG in patients with hyperkalemia. The model was based on several parameters, including electrophysiological dynamics, transmural differences in cell type, fiber orientation, and fibrosis at varying extracellular potassium concentrations ([K+]o) ranging between 5.4 and 10.5 mmol/L. A human wedge model of the anterior ventricular wall, including both ventricles and the RVOT, was created using a reference geometry (normal young male), available for the ECGSIM software. 20 The mesh contained 281 191 nodes and 1 460 832 elements with a mean edge length of 290.8AE296.6 lm. Human ventricular cell dynamics and action potential morphologies of cell types were simulated using the O'Hara-Rudy model, 21 with modifications in the sodium current suggested by Dutta et al, 22 which enabled realistic simulations under hyperkalemic conditions. Ventricular activation sequences were based on Cardone-Noott et al, 23 being initiated in 3 areas in our model. Anisotropic conduction attributed to fiber orientation changes was incorporated into the model using an anisotropy ratio of 10:1, D||:D⊥, where D|| and D⊥ are the longitudinal and transverse diffusion coefficients, respectively. Therefore, propagation in any direction of the three-dimensional model depended on fiber direction. The RVOT diffusion coefficient was 25% of either ventricle, keeping the same anisotropy ratio. 10.5 mmol/L), and increasing I to conductance gradient from baseline to the maximal conductance, 1.50 mS/lF. Monodomain equations were solved using the Forward-Euler algorithm with a fixed time step of 0.01 ms on a graphic processors unit (GPU Tesla K20 5GRAM DDR5). 26 Three virtual electrodes were positioned at standard electrode locations for the calculation of pseudo-ECGs V1, V2, and V3. Figure 1 shows ECG data from precordial lead recordings from each patient displaying a BrPh ECG at the time of peak hyperkalemia. None of the patients had a family history of BrS, cardiac arrhythmias, or syncope. Baseline clinical characteristics, hospital admission reason, and etiology of hyperkalemia are shown in Table 1 . In all cases, ECG changes were transient and disappeared after plasma serum K + levels returned to normal ( Table 2 ).
Statistical Analyses
Most patients were middle aged (56.4AE16 years old) men (79%), presenting a critically ill state on admission. In fact, 3 were brought to the emergency room because of out-ofhospital sudden cardiac arrest. The most frequent primary etiology of hyperkalemia was decompensated renal function. Six (43%) patients died during admission for different reasons (Table 1) : Two patients presented postanoxic encephalopathy, 1 had recurrent cardiac arrest at the time of arrival in the emergency room, and 2 presented septic shock (patients 6 and 9). One patient died after prolonged admission because of metastatic testicular cancer. Patient 3 died 3 months after hospital discharge because of terminal hepatic disease. We contacted 8 of the surviving patients, and a flecainide test was finally performed in 5 (of the other 3, 1 was dismissed because of severe neurologic chronic sequelae and 2 lived overseas). The flecainide test was negative in 4 patients and positive in 1. Patient 4 was a 53-year-old male admitted for diabetic ketoacidosis with hyperkalemia (K + , 6.9 mmol/L; serum pH, 6.89). He presented a BrPh pattern on admission ( Figure 2A ), which was normalized after correction of the serum K + (4.5 mmol/L; serum pH, 7.1; Figure 2B ). Several weeks after hospital discharge, while the patient was clinically stable, a flecainide test (2-mg/kg intravenous infusion over 10 minutes) uncovered a type 1 Brugada pattern ( Figure 2C ).
Clinical Characteristics and Outcome of Patients With Hyperkalemic BrPh Versus Severe Hyperkalemia With Non-BrPh Pattern
During 2013, 245 patients presented severe hyperkalemia of 46 459 admitted to our institution (0.53%). Of those, 44 (18%) had an ECG recording available at the time of peak hyperkalemia. Table 3 shows baseline characteristics of BrPh patients (group 1) and severe hyperkalemic patients without BrPh (group 2). Compared with group 2 patients, BrPh patients were younger and had higher serum K + values (1 mmol/L higher on average), lower pH, and less chronic kidney disease; hypertension tended to be less prevalent and so was the use of angiotensin-receptor blockers. On ECG, BrPh hyperkalemic patients showed wider QRS, and frequently presented abnormal QRS axis and greater T-wave height compared with nonBrPh hyperkalemic patients (Table 3 ). Multivariate analysis (Tables 3 and 4) .
Of 15 patients with BrPh, 6 (40%) had malignant arrhythmias (3 presented as sudden cardiac arrest): 4 had ventricular tachycardia, 1 ventricular fibrillation, and 1 high-degree atrioventricular block. In group 2, 11 patients (25%) had malignant arrhythmias: 7 high-degree atrioventricular block, 3 ventricular tachycardia, and 1 ventricular fibrillation. Thus, patients with BrPh had a higher likelihood of developing In contrast, in the fibrotic case, conduction slowing or block promoted ST-segment elevation on V1 and V2, consistent with the classical BrS descriptors. In Figure 3B , the corresponding action potential duration (APD) maps show a progressive global decrease in the APD as [K + ] o is increased. As illustrated also by the action potential recordings at specific locations, fibrosis intensified both the APD shortening and the activation delay at the RVOT and its immediate vicinity.
Role of I to
Previous evidence has implicated the epicardial-to-endocardial I to gradient within the right ventricle in the pathogenesis and phenotypic expression of BrS. 2 We therefore conducted additional simulations to test the consequences of combining hyperkalemia with increased epicardial I to gradient at the RVOT in the presence and absence of fibrosis. The gradient was established by increasing the baseline value of the epicardial band to 0.30, 0.70, and 1.50 mS/lF, while leaving the endocardium at the basal level (0.08 mS/lF). In Figure 4A , under basal [K + ] o conditions, we had to increase the maximal I to conductance up to 1.50 mS/lF, to enable BrPh, a value that is characteristic of BrS modeling. 4 Increasing I to produced a progressively exaggerated action potential notch (arrow) at the RVOT while the rest of the tissue was undergoing initial depolarization during the plateau ( Figure 4B ). On the electrograms, these events coincided with ST-segment elevation ( Figure 4A ). As illustrated in Figure 5 , the combined effects of fibrosis, elevated [K + ] o -induced membrane depolarization leading to reduced excitability, and increased I to density greatly facilitated the appearance of BrPh on leads V1 to V2. In Figure 5A , a BrPh pattern was already evident on V1 and V2 at 55% fibrosis even when the epicardial I to was at baseline (0.08 mS/lF). The effect was even greater when fibrosis at the RVOT was increased to 75%. Here, ST-segment elevation occurred at 10 mmol/L [K + ] o because of extreme conduction delay at the RVOT ( Figure 5B) . In additional simulations, we assessed the effects of fibrosis and I to current gradient on the entire ventricular wall. The effects were similar to those observed when such changes were only applied to the RVOT. The relative increase in I to over the entire epicardial surface with respect to the endocardium simulated characteristics of the Brugada pattern (Figure 6 ). At baseline, the I to gradient caused an increase in the duration of the epicardial action potential by increasing the transmembrane potassium outflow during the whole plateau phase. This slightly elevated the ST segment and decreased the T-wave amplitude, even depressing the T wave on V3. However, the [K + ] o increase also depolarized the membrane potential and reduced the availability of the sodium channels. Consequently, conduction velocity was reduced and the APD was abbreviated, with the appearance of regions of activation failure. Fibrosis throughout the ventricular surface slowed activation and wavefront propagation (Figure 7) , prolonging the QRS and delaying T-wave activation more than when fibrosis was present in the RVOT. When the [K + ] o was raised to a pathological threshold, conduction slowed further with propagation failure in areas with less excitable cardiac tissue, including the RVOT and its surroundings. ST-segment elevation did not occur under these conditions because of the conduction slowing generated. 
Proarrhythmic Risk of BrPh Pattern Attributed to Hyperkalemia
The foregoing simulations provide insight into the mechanism underlying the observed predisposition of BrPh patients to malignant arrhythmias, as illustrated in the following clinical example: Patient 5 (Table 1) arrived at the emergency department after suffering an out-of-hospital sudden death episode, showing complex ventricular rhythm with wide QRS. An intravenous bolus of adenosine (12 mg) transiently slowed the rhythm and normalized the QRS complex duration. When the adenosine effect faded, the ventricular rhythm accelerated and resumed with progressive QRS widening ( Figure 8A through 8C). The patient had a low conscience level, was tachypneic, and had a blood pressure of 100/55 mm Hg. Urgent blood analyses showed serum K + levels of 9.1 mmol/L.
He was treated with intravenous fluids (2 L of glucosaline), intravenous sodium bicarbonate, 1 g of intravenous calcium chloride, and insulin. One hour later, the K + level was 8.1 mmol/L and the ECG showed a BrPh pattern ( Figure 8C ). The observed changes were consistent with adenosine activation of I K,Ado channels, which, by increasing K + conductance, hyperpolarized the cell membrane, abbreviated the APD and the refractory period, and inhibited spontaneous pacemaker discharge, leading to significant QRS narrowing and transient sinus arrest. 27 This finding was further confirmed by our computer simulations. In Figure 9 , we used a fibrotic RVOT with hyperkalemic conditions at [
A burst stimulus train with an extra stimulus at 400 ms increased electrogram fractionation and caused unidirectional block that allowed stable reentry formation at the RVOT.
Discussion
The main findings of this study are as follows: 1. In patients with severe hyperkalemia resulting from a critical medical condition, the presence of a BrS phenotype is associated with a high prevalence of malignant arrhythmias and all-cause mortality. 2. In surviving patients, the characteristic Brugada levels and male sex were independent predictors for the presence of BrPh ECG in patients with severe hyperkalemia. 5. As shown by the response to adenosine infusion and computer simulations, ECG manifestations of systemic hyperkalemia are a consequence of the depolarized resting membrane potential and reduced sodium-channel availability for action potential activation, which results in delayed and heterogeneous conduction, or block, particularly in the presence of fibrosis at the RVOT.
Systemic Hyperkalemia Causing BrPh
Systemic hyperkalemia is most frequently found in patients with chronic and acute renal failure and/or concomitant treatments with nephrotoxic medications or K-sparing drugs. The classical electrocardiographic manifestations of hyperkalemia were first documented in the early 1950s by the presence of peaked T waves, shortened QT interval, lengthening of the PR interval, loss of P waves, and widening of the QRS complex. 28 Moreover, Levine et al also described the presence of the "dialyzable" current of injury resembling acute myocardial infarction or pericarditis. 29 However, Littmann et al reported the first consecutive series that recognized the similarities between the classic BrS ECG manifestations and those occasionally shown in the context of severe hyperkalemia. 11 In agreement with this and other studies, 10,11,30 we found that BrPh was most likely present in critically ill male patients with severe decompensation of their renal function and/or malignancies, with high mortality mostly related to their underlying clinical condition. In addition, we found that compared with hyperkalemic patients without Brugada ECG, the BrPh patients presented in males with higher serum K + values (1 mmol/L higher on average). Moreover, lower pH was also strongly related to the development of BrPh. These data, together with the presence of other outcome predictors, such as younger age, lower hypertension prevalence, and lesser chronic renal disease, further confirm the importance of acute increments in K + levels, which might be underestimated in terminal renal failure patients. 31 Given 32 The findings of our multivariant analyses further support the predominant role of male sex and higher hyperkalemia levels, together with the role for the acid group presence on the reduction of channel conductance favoring the occurrence of malignant ventricular arrhythmias, as shown in our simulations. 33 We compared the clinical manifestations, ECG, and outcomes (malignant arrhythmias and mortality) of BrPh patients with those of severe hyperkalemic patients (K + ≥6.5 mmol/L) without BrS phenotype. Overall, patients with the BrPh ECG had a grave prognosis with a short-to mid-term fatality rate of 51% not only related to the baseline clinical disease, but also to the clinical impact of malignant ventricular arrhythmias. Moreover, although patients presenting with BrPh had a higher likelihood of developing malignant arrhythmias than non-BrPh patients (43% versus 25%), in-hospital mortality was similar because of the poor clinical status in both groups. We compared the ECG of hyperkalemic patients and found that patients showing a BrPh had a wider QRS, and frequently presented abnormal QRS axis and a greater T-wave height compared with non-BrPh hyperkalemic patients (Table 3) . This contrasted with patients with inheritable BrS that usually have mildly widened QRS complexes, but normal QRS axes on an otherwise normal ECG. 11, 36 Thus, the presence of moderateto-severe hyperkalemia, especially with a Brugada ECG pattern or atypical ST-segment elevation on the right precordial leads without BrS, should be aggressively treated and considered a risk factor for development of life-threatening cardiac arrhythmias. This is in agreement with previous studies showing that presence of an aVR sign and/or STsegment elevation on the right precordial leads pattern reflects more right ventricular conduction delay and electrical heterogeneity, increasing the risk for developing arrhythmic events.
18,19

Mechanism of Proarrhythmic Risk of BrPh Pattern Attributed to Hyperkalemia
To our knowledge, the relationship between hyperkalemia and the BrS ECG manifestations had not yet been systematically investigated. Together, the clinical results and computer simulations presented above provide mechanistic insight into the manifestation of electrolytic dysregulation causing Brugada phenotype. Even in the absence of genetic disease (eg, inheritable SCN5A mutations), delays in ventricular activation, and propagation failure at the RVOT, magnified by the presence of hyperkalemia and, possibly, low acid base state, promote the required electrophysiological changes, including APD shortening, membrane depolarization, and reduced sodiumchannel availability, which enable the manifestation of BrPh ECG, an effect that is magnified by RVOT fibrosis. Introduction of fibrotic tissue reduced the excitability of the RVOT and slowed CV, leading to a ST-segment elevation on V1 and V2 leads, creating the substrate for inducibility of malignant arrhythmias. In agreement with previous clinical reports, computer simulations showed that programmed stimulation caused electrogram fractionation and unidirectional block to initiate stable reentry formation without the need of an extrasytole. 8 Unexcitability attributed to the high concentration of potassium and its propensity to the generation of arrhythmias agrees with recent reports. 12 These results are supported by simulations by other groups showing that activation delay and right ventricular excitation failure attributed to current-load mismatch secondary to decrease in calcium current or increase in I to can cause BrS. 16, 17 Similar mechanisms could be responsible for other types of BrPh, with low availability of sodium channels given that it occurs during hypothermia or acidosis in ischemic regions. The relative increase in I to density at the RVOT reduced the need for slow conduction caused by hyperkalemia and resulted in spatial gradients of membrane voltage giving rise to the typical ST-segment elevation found in BrPh. In agreement with BrS, the strong sex-related predominance found in the BrPh indirectly supports the prominence of the transient outward current-mediated action potential notch in the right ventricular epicardium of males. 37 Moreover, the combination of abnormal repolarization and abnormal conduction not only explains the phenotypic manifestation of the BrPh, but also its clinical arrhythmic outcomes in the form of sustained ventricular reentrant patterns. On one hand, the presence of steep repolarization gradients causes asymmetry in excitability that gives rise to unidirectional block. On the other, slow conduction shortens the wavelength of the reentrant AP facilitating reentrant stabilization (Figures 8 and 9 ). Therefore, severe hyperkalemia leading to inactivation of the sodium channel in conjunction with presence of subtle structural abnormalities of the FVOT were responsible for the BrPh manifestation and reentrant arrhythmia occurrence in this setting.
Limitations
The observational and retrospective nature of the study prevented clinical data collections (ie, acid group value) and reduced the number of available ECGs. Although the computer simulations support the theory that RVOT has a major role producing Brugada patterns, further clinical data (histological and image data) and cellular studies are necessary to accurately define the substrate of this clinical entity in this environment. 15, 38 For example, imaging (eg, magnetic resonance imaging) data in patients presenting with a BrPh ECG could have shown enhanced fibrosis in the RVOT, as predicted by the modeling results. However, magnetic resonance imaging was nearly impossible in our study because of the fact that many of the patients were critically ill and had a very poor outcome, which substantially limited the number of patients available to study.
Conclusion
This report adds to our understanding of the electrocardiographic features of hyperkalemic BrPh patients. In patients with severe hyperkalemia attributed to critical medical conditions, a BrPh ECG is associated with a high prevalence of malignant arrhythmias and high all-cause mortality. BrPh ECG manifestations in patients with hyperkalemia are attributed to depolarized resting membrane potential and reduced availability of inward sodium channels. Although I to elevation contributes, it is not essential to generate the hyperkalemic Brugada phenotype.
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